{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/33573"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/33573","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"Healthcare Professional Perspectives on Access to Low Molecular Weight Heparin During Pregnancy and Postpartum: A Qualitative Description of Drug Access and Health Equity in Ontario","abstract":"Background: Low molecular weight heparin (LMWH) is a first-line anticoagulant for the treatment and prevention of venous thromboembolism during pregnancy and postpartum, a leading cause of maternal mortality and morbidity in high-income settings. This study sought to explore healthcare professionals’ (HCPs) perspectives on access to LMWH during pregnancy and postpartum in Ontario, Canada, where prior research suggests ongoing accessibility concerns in the general population. Methods: A qualitative descriptive study was conducted using semi-structured interviews with Ontario HCPs caring for people who require LMWH during pregnancy and postpartum. Interviews were audio-recorded, transcribed verbatim, and analyzed using rapid qualitative analysis. Results: Seventeen HCPs (physicians, nurses, pharmacists) from thirteen Ontario facilities were interviewed. Participants identified multi-level factors influencing access to LMWH across key access stages, including risk identification, access to specialist care, adjudication, cost navigation, pharmacy access, and adherence. Factors related to adjudication and cost navigation were among the most emphasized by HCPs, who reported barriers associated with insufficient and delayed public coverage, and reliance on workarounds, such as compassionate supply programs, samples, and broad application of limited-use criteria. Participants also highlighted geographic barriers to specialized perinatal care, limited availability in pharmacies, variability in HCPs’ awareness of workarounds, and factors influencing adherence, including patients’ risk perception, and their willingness and capacity to overcome the logistical challenges associated with self-injection during pregnancy and postpartum. Conclusions: Access to LMWH during pregnancy and postpartum is influenced by factors across system-, facility, HCP-, and patient levels. Findings from this qualitative descriptive study reveal opportunities to improve equitable access to essential medications during pregnancy and postpartum, and may inform clinical practice, policy, and public health efforts.","abstract_html":"Background: Low molecular weight heparin (LMWH) is a first-line anticoagulant for the treatment and prevention of venous thromboembolism during pregnancy and postpartum, a leading cause of maternal mortality and morbidity in high-income settings. This study sought to explore healthcare professionals’ (HCPs) perspectives on access to LMWH during pregnancy and postpartum in Ontario, Canada, where prior research suggests ongoing accessibility concerns in the general population. Methods: A qualitative descriptive study was conducted using semi-structured interviews with Ontario HCPs caring for people who require LMWH during pregnancy and postpartum. Interviews were audio-recorded, transcribed verbatim, and analyzed using rapid qualitative analysis. Results: Seventeen HCPs (physicians, nurses, pharmacists) from thirteen Ontario facilities were interviewed. Participants identified multi-level factors influencing access to LMWH across key access stages, including risk identification, access to specialist care, adjudication, cost navigation, pharmacy access, and adherence. Factors related to adjudication and cost navigation were among the most emphasized by HCPs, who reported barriers associated with insufficient and delayed public coverage, and reliance on workarounds, such as compassionate supply programs, samples, and broad application of limited-use criteria. Participants also highlighted geographic barriers to specialized perinatal care, limited availability in pharmacies, variability in HCPs’ awareness of workarounds, and factors influencing adherence, including patients’ risk perception, and their willingness and capacity to overcome the logistical challenges associated with self-injection during pregnancy and postpartum. Conclusions: Access to LMWH during pregnancy and postpartum is influenced by factors across system-, facility, HCP-, and patient levels. Findings from this qualitative descriptive study reveal opportunities to improve equitable access to essential medications during pregnancy and postpartum, and may inform clinical practice, policy, and public health efforts.","abstract_has_math":false,"creators":["Woolley, Emma"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Health Care Research Methods","school":null,"contributors":[],"advisors":["D'Souza, Rohan"],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-18T19:40:15Z","subjects":["Medication access","drug policy","pregnancy and postpartum"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/7671"],"render_values":[{"text":"https://doi.org/10.71548/7671","href":"https://doi.org/10.71548/7671","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/11375/33573","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/11375/33573","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F33573","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["D'Souza, Rohan"]},{"key":"dc:contributor.department","label":"Department","values":["Health Care Research Methods"]},{"key":"dc:creator","label":"Author","values":["Woolley, Emma"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-09-21T14:35:54Z"]},{"key":"dc:date.issued","label":"Date","values":["2026"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Medication access","drug policy","pregnancy and postpartum"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/11375/33573","https://doi.org/10.71548/7671"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Background: Low molecular weight heparin (LMWH) is a first-line anticoagulant for the treatment and prevention of venous thromboembolism during pregnancy and postpartum, a leading cause of maternal mortality and morbidity in high-income settings. This study sought to explore healthcare professionals’ (HCPs) perspectives on access to LMWH during pregnancy and postpartum in Ontario, Canada, where prior research suggests ongoing accessibility concerns in the general population. Methods: A qualitative descriptive study was conducted using semi-structured interviews with Ontario HCPs caring for people who require LMWH during pregnancy and postpartum. Interviews were audio-recorded, transcribed verbatim, and analyzed using rapid qualitative analysis. Results: Seventeen HCPs (physicians, nurses, pharmacists) from thirteen Ontario facilities were interviewed. Participants identified multi-level factors influencing access to LMWH across key access stages, including risk identification, access to specialist care, adjudication, cost navigation, pharmacy access, and adherence. Factors related to adjudication and cost navigation were among the most emphasized by HCPs, who reported barriers associated with insufficient and delayed public coverage, and reliance on workarounds, such as compassionate supply programs, samples, and broad application of limited-use criteria. Participants also highlighted geographic barriers to specialized perinatal care, limited availability in pharmacies, variability in HCPs’ awareness of workarounds, and factors influencing adherence, including patients’ risk perception, and their willingness and capacity to overcome the logistical challenges associated with self-injection during pregnancy and postpartum. Conclusions: Access to LMWH during pregnancy and postpartum is influenced by factors across system-, facility, HCP-, and patient levels. Findings from this qualitative descriptive study reveal opportunities to improve equitable access to essential medications during pregnancy and postpartum, and may inform clinical practice, policy, and public health efforts."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Master of Public Health (MPH)"]},{"key":"dc:title","label":"Title","values":["Healthcare Professional Perspectives on Access to Low Molecular Weight Heparin During Pregnancy and Postpartum: A Qualitative Description of Drug Access and Health Equity in Ontario"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["D'Souza, Rohan"],"dc:contributor.department":["Health Care Research Methods"],"dc:creator":["Woolley, Emma"],"dc:date.accessioned":["2026-09-21T14:35:54Z"],"dc:date.issued":["2026"],"dc:description.abstract":["Background: Low molecular weight heparin (LMWH) is a first-line anticoagulant for the treatment and prevention of venous thromboembolism during pregnancy and postpartum, a leading cause of maternal mortality and morbidity in high-income settings. This study sought to explore healthcare professionals’ (HCPs) perspectives on access to LMWH during pregnancy and postpartum in Ontario, Canada, where prior research suggests ongoing accessibility concerns in the general population. Methods: A qualitative descriptive study was conducted using semi-structured interviews with Ontario HCPs caring for people who require LMWH during pregnancy and postpartum. Interviews were audio-recorded, transcribed verbatim, and analyzed using rapid qualitative analysis. Results: Seventeen HCPs (physicians, nurses, pharmacists) from thirteen Ontario facilities were interviewed. Participants identified multi-level factors influencing access to LMWH across key access stages, including risk identification, access to specialist care, adjudication, cost navigation, pharmacy access, and adherence. Factors related to adjudication and cost navigation were among the most emphasized by HCPs, who reported barriers associated with insufficient and delayed public coverage, and reliance on workarounds, such as compassionate supply programs, samples, and broad application of limited-use criteria. Participants also highlighted geographic barriers to specialized perinatal care, limited availability in pharmacies, variability in HCPs’ awareness of workarounds, and factors influencing adherence, including patients’ risk perception, and their willingness and capacity to overcome the logistical challenges associated with self-injection during pregnancy and postpartum. Conclusions: Access to LMWH during pregnancy and postpartum is influenced by factors across system-, facility, HCP-, and patient levels. Findings from this qualitative descriptive study reveal opportunities to improve equitable access to essential medications during pregnancy and postpartum, and may inform clinical practice, policy, and public health efforts."],"dc:description.degree":["Master of Public Health (MPH)"],"dc:identifier.uri":["https://hdl.handle.net/11375/33573","https://doi.org/10.71548/7671"],"dc:subject":["Medication access","drug policy","pregnancy and postpartum"],"dc:title":["Healthcare Professional Perspectives on Access to Low Molecular Weight Heparin During Pregnancy and Postpartum: A Qualitative Description of Drug Access and Health Equity in Ontario"],"dc:type":["Thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:40:15Z"}